Keep up to date on the latest medical news at MDLinx - FREE!


  • Stay current on the latest medical literature, research and clinical news
  • MD jobs and physician job search at our new medical job Career Center
  • Receive invitations to paid market research
  • Search Clinical Trials and Medical Conferences

register to view free medical at articles at MDLinx

Follow Us

Posts by category

MDLinx Blog - Medical News and more.

Current Articles | RSS Feed RSS Feed

FDA: Revised recommendations for cardiovascular monitoring and use of multiple sclerosis drug Gilenya (fingolimod)

  
  
  
  
  

FDA issues drug safety annoucement for multiple sclerosis drug Gilenya (fingolimod).

The U.S. Food and Drug Administration (FDA) has completed its evaluation of a report of a patient who died after the first dose of multiple sclerosis drug Gilenya (fingolimod). The agency also has evaluated additional clinical trial and postmarket data for Gilenya, including reports of patients who died of cardiovascular events or unknown causes. FDA could not definitively conclude that Gilenya was related to any of the deaths (see Data Summary, below). However, based on its reevaluation of the data, FDA remains concerned about the cardiovascular effects of Gilenya after the first dose. Data show that, although the maximum heart rate lowering effect of Gilenya usually occurs within 6 hours of the first dose, the maximum effect may occur as late as 20 hours after the first dose in some patients (See Data Summary).

For this reason, Gilenya is now contraindicated (FDA advises against its use) in patients with certain pre-existing or recent (within last 6 months) heart conditions or stroke, or who are taking certain antiarrhythmic medications. See CONTRAINDICATION section of the drug label2.

FDA continues to recommend that all patients starting Gilenya be monitored for signs of a slow heart rate (bradycardia) for at least 6 hours after the first dose. FDA is now recommending hourly pulse and blood pressure measurement for all patients starting Gilenya. Electrocardiogram (ECG or EKG) testing should be performed prior to dosing and at the end of the observation period. Cardiovascular monitoring should continue until any symptoms resolve.

Read full release here.

All Posts

Trending Medical Articles

Monday, Mar 31, 2014
Journal of Oral Implantology, 03/31/2014 Nayak AG, et al. – Gaps and hollow spaces at the implant abutment interface will act as a bacterial reservoir that may cause peri–implantitis. Hence, the sealing ability of O–ring (in addition to polysiloxane) and GapSeal (an antibacterial sealing gel) was evaluated. The data thus obtained were subjected to statistical analysis by...Read More
Tuesday, Apr 8, 2014
Annals of Rheumatic Diseases, 04/08/2014 Saevarsdottir S, et al. – To study clinical predictors for radiographic progression after 1 year in an early rheumatoid arthritis (RA) trial. In addition to previously described predictors, the authors identified smoking as a strong independent risk factor for radiographic progression in early RA. Methods In the SWEFOT trial population, disease...Read More
Monday, Apr 7, 2014
Physiotherapy, 04/07/2014 Spencer LM, et al. – The aim of this study is to determine if there was an increase in walk distance when two incremental shuttle walk tests (ISWTs) were performed at the commencement of a maintenance exercise program and at three, six and 12–month assessments. The increase in walk distance when a second ISWT was performed at zero and three months...Read More
Tuesday, Apr 15, 2014
Breast Cancer Research and Treatment, 04/15/2014 Guha P, et al. – The authors show that nicotine induces the expression of galectin–3 (an anti–apoptotic β–galactoside–binding lectin) in breast cancer cell line and in primary tumors from breast cancer patients. Galectin–3 or its upstream signaling molecule STAT3 or α9nAChR could be a potential...Read More